Albert Bourla

Albert Bourla, CEO of Pfizer, shares insights from his pivotal role during the COVID-19 pandemic, particularly in vaccine development. He discusses the extraordinary pressure and challenges faced while ensuring safety and efficacy amidst public skepticism. Bourla emphasizes the need for transparency to rebuild trust in pharmaceuticals and the delicate balance between personal choice and public health mandates. He also delves into advancements in COVID treatments, contrasting Pfizer’s antiviral Paxlovid with other controversial options, and reflects on the broader meaning of life and innovation.

Scott Bultright, CEO of Chipotle, shares insights on the company's impressive financial performance and future growth strategies. Albert Bourla, Chairman and CEO of Pfizer, discusses the pharma sector's rebounds and innovative treatments, including their promising cancer research. Ian Kryze, CEO of Mattel, highlights the company's strong earnings and exciting plans for expansion, like new entertainment ventures. Together, they present a dynamic view of industry trends, trade impacts, and strategic innovations shaping their respective markets.

Albert Bourla, Chairman and CEO of Pfizer, joins the discussion to share insights on Pfizer's strategic acquisition of Metsera for up to $10 billion, targeting the obesity drug market. He emphasizes the company's robust development capabilities and outlines the potential for product differentiation in obesity therapies. Bourla tackles regulatory implications and competitive dynamics with major players like Novo Nordisk. The hosts also explore market reactions to a potential government shutdown deal and the challenges facing the tech sector amid AI valuation concerns.